Inventiva resumes Phase 3 study for NASH drug, stock up 6% [Seeking Alpha]
Inventiva S.A. - American Depository Shares (IVA)
Company Research
Source: Seeking Alpha
Phase 3 study for its drug lanifibranor in the treatment of non-alcoholic steatohepatitis, or NASH. Inventiva had paused the trial in February after a patient suffered a suspected adverse reaction. The patient is expected to make a full recovery, the company said in a statement released late Thursday. The trial, called NATiV3, will now proceed with certain modifications, including liver monitoring every six weeks and the exclusion of newly screened patients diagnosed or with a predisposition to autoimmune liver and thyroid disease. Inventiva said screening and randomization have resumed at certain US sites and are expected to restart at other sites in the next few weeks. The last patient visit for the trial is targeted for the first half of 2024. Lanifibranor belongs to a class of drugs called PPAR agonists. Other companies developing liver-targeting PPAR agonists include Gilead Sciences ( GILD ), through its recently acquired Cymabay unit, and France's Genfit ( GNFT OTCPK:GNF
Show less
Read more
Impact Snapshot
Event Time:
IVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IVA alerts
High impacting Inventiva S.A. - American Depository Shares news events
Weekly update
A roundup of the hottest topics
IVA
News
- Non-Alcoholic Steatohepatitis (NASH) Pipeline Insight, 2024 Featuring 100+ Companies and 110+ Pipeline Drugs Including Lanifibranor (Inventiva Pharma), MSDC-0602K (Cirius Therapeutics), TERN-501 (Terns Pharma) [Yahoo! Finance]Yahoo! Finance
- Inventiva S.A. (NASDAQ: IVA) had its price target raised by analysts at Canaccord Genuity Group Inc. from $12.00 to $20.00. They now have a "buy" rating on the stock.MarketBeat
- Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F [Yahoo! Finance]Yahoo! Finance
- Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-FGlobeNewswire
- Inventiva S.A. (NASDAQ:IVA) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
IVA
Sec Filings
- 5/3/24 - Form SC
- 4/3/24 - Form 20-F
- 3/27/24 - Form 6-K
- IVA's page on the SEC website